UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                   FORM 10-QSB



[X]      QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE
         ACT OF 1934

         For the quarterly period ended September 30, 2003

[ ]      TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE EXCHANGE ACT

         For the transition period from ___________  to ____________.

         Commission file number: 0-26807

                                 CYTOGENIX, INC.
        (Exact name of small business issuer as specified in its charter)

           NEVADA                                          76-0484097
           ------                                          ----------
(State or other jurisdiction of                          (IRS Employer
 incorporation or organization)                            Identification No.)

                  9881 South Wilcrest, Houston, Texas       77099
                  -----------------------------------       -----
               (Address of principal executive offices)   (Zip Code)

         Issuer's telephone number, including area code: (281) 988-6118

         The number of shares  outstanding  of each of the  issuer's  classes of
common equity, as of the latest practicable date:

         As of September  30,  2003,  95,719,333  shares of the issuer's  common
stock was outstanding.

         Transitional Small Business Disclosure Format (check one): Yes   No  X
                                                                       ---   ---









<PAGE>

<TABLE>

<CAPTION>

                                CYTOGENIX, INC.
                         (A DEVELOPMENT STAGE COMPANY)

                                  BALANCE SHEET

                               SEPTEMBER 30, 2003

                                   (Unaudited)

                                     ASSETS
<S>                                                                                     <C>

  CURRENT ASSETS:
             Cash                                                                       $       178,492
Property and equipment, net of $164,181 accumulated depreciation                                 63,775
                                                                                        ---------------
     Total assets                                                                       $       242,267
                                                                                        ===============

                            LIABILITIES AND STOCKHOLDERS' DEFICIT
CURRENT LIABILITIES:
  Accounts payable                                                                      $       223,035
  Accrued expenses                                                                              405,700
                                                                                        ---------------
    Total current liabilities                                                                   628,735
                                                                                        ---------------

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS' DEFICIT:
  Common stock, $.001 par value; 150,000,000 shares authorized, 95,719,333 shares
    issued and outstanding                                                                       95,719
  Additional paid-in capital                                                                 16,176,333
   Treasury stock                                                                              (629,972)
  Deficit accumulated during the development stage                                          (16,028,548)
                                                                                        ----------------
    Total stockholders' deficit                                                                (386,468)
                                                                                        ---------------

      Total liabilities and stockholders' deficit                                       $       242,267
                                                                                        ===============
</TABLE>



<PAGE>

<TABLE>

<CAPTION>

                                 CYTOGENIX, INC.
                          (A DEVELOPMENT STAGE COMPANY)

                            Statements of Operations
        Three and Six Months Ended Se[tember 30, 2003 and 2002 and Period
          From February 10, 1995 (Inception) Through September 30, 2003
                                   (Unaudited)

                                                                                                                Inception
                                                   Three Months                      Nine Months                 Through
                                                  September 30,                     September 30,              September 30,
                                         ---------------------------------  -------------------------------  -----------------
                                              2003              2002            2003             2002              2003
                                         ---------------   ---------------  --------------   --------------  -----------------
<S>                                      <C>               <C>              <C>              <C>             <C>

 Revenues                                $       80,000    $            -   $        80,000   $       1,700  $         82,575

 Costs and Expenses:
     Research and development                   134,765           524,723         324,472        1,085,009          5,120,440
     General and administrative                 378,051           491,273         912,542        1,383,786         10,440,773
     Depreciation and amortization               10,329             8,095          29,340           28,805            196,971
     Impairment expense                               -                 -               -                -            345,588
     Equity in losses of joint venture                -                 -               -                -             10,000
                                         ---------------   ---------------  --------------   --------------  -----------------
 Loss From Operations                          (443,145)       (1,024,091)     (1,186,354)      (2,495,900)       (16,031,197)

 Other Income:
     Gain on sale of security                         -                 -               -                -                881
     Interest Income                                135                 -              135                                135
     Dividend income                                  -                 -               -                -              1,633
                                         ---------------   ---------------  --------------   --------------  -----------------
 NET LOSS                                $     (443,010)   $   (1,024,091)  $  (1,186,219)   $  (2,495,900)  $    (16,028,548)
                                         ===============   ===============  ==============   ==============  =================
 Net loss per share:
      Basic and diluted                  $        (0.01)   $        (0.02)  $       (0.01)   $       (0.05)
                                         ===============   ===============  ==============   ==============


 Weighed average shares outstanding:
     Basic and diluted                       91,730,147        58,877,768      83,557,542       53,304,298
                                         ===============   ===============  ==============   ==============
</TABLE>



<PAGE>

<TABLE>

<CAPTION>

                                 CYTOGENIX, INC.
                          (A DEVELOPMENT STAGE COMPANY)


                            Statements of Cash Flows
        1.       Nine Months Ended September 30, 2003 and 2002 And Period

        2.       From February 10, 1995 (Inception) Through September 30, 2003

                                   (Unaudited)
                                                                                                      Inception
                                                                                                       Through
                                                                2003                2002                 2003
                                                         ------------------  ------------------   -----------------
<S>                                                      <C>                 <C>                  <C>

Operating Activities:
   Net loss                                              $      (1,186,219)  $      (2,495,900)   $    (16,028,548)
   Adjustments to reconcile net loss to net cash
      used in operating activities:
      Depreciation and amortization                                 29,340              45,546             196,971
      Impairment expense                                                 -                   -             345,588
      Stock issued for services                                    390,428             218,276           6,636,314
      Stock option expense                                               -                   -           1,797,300
      Equity in losses of joint venture                                  -                   -              10,000
      Changes in operating assets and liabilities:
         Deferred consulting expense                                     -           1,350,265                   -
         Prepaid expenses
                                                                     8,214            (102,518)   -
         Accounts payable & accrued expenses                       (33,020)           (318,543)            761,348
                                                         ------------------  ------------------   -----------------
Net cash used in operating activities                             (791,257)         (1,302,874)         (6,281,027)
                                                         ------------------  ------------------   -----------------
Investing Activities:
   Purchase of property and equipment                                    -           (   8,535)           (227,957)
   Issue note receivable                                                 -                   -             (25,100)
   Investment in joint venture                                           -                   -             (10,000)
                                                         ------------------  ------------------   -----------------
Net cash provided by used in investing activities                        -           (   8,535)           (263,057)
                                                         ------------------  ------------------   -----------------
Financing Activities Provided by:
   Proceeds from notes payable                                           -                   -             250,000
   Payments on notes payable                                             -                   -            (250,000)
   Treasury shares sold                                                  -                   -           1,290,568
   Purchase of treasury shares                                           -                   -             (60,000)
   Sale of common stock                                            974,749           1,295,721           5,339,508
   Proceeds from loan from related party                                 -                   -               5,000
   Payment of loan from related party                               (5,000)                  -              (5,000)
   Contributions to capital                                              -                   -             152,500
                                                         ------------------  ------------------   -----------------
Net cash provided by financing activities                          969,749           1,295,721           6,722,576
                                                         ------------------  ------------------   -----------------
Net Change in Cash                                                 178,492             (15,688)            178,492






<PAGE>

                                 CYTOGENIX, INC.
                          (A DEVELOPMENT STAGE COMPANY)


Cash, beginning of period                                                -              15,688                   -
                                                         ------------------  ------------------   -----------------
Cash, end of period                                      $         178,492   $               -    $        178,492
                                                         ------------------  ------------------   -----------------

NonCash Transactions:
   Common stock issued for debt                          $               -   $               -    $        135,990
 Received treasury stock for note receivable             $               -   $               -              25,100
   Common stock issued for patent                        $               -   $               -             375,000

</TABLE>









<PAGE>

                                 CYTOGENIX, INC.
                          (A DEVELOPMENT STAGE COMPANY)
                          NOTES TO FINANCIAL STATEMENTS
                                   (Unaudited)

         NOTE 1 - BASIS OF PRESENTATION

         The accompanying  unaudited interim financial  statements of CytoGenix,
         Inc.  ("CytoGenix")  have been prepared in accordance  with  accounting
         principles  generally  accepted in the United States of America and the
         rules of the Securities and Exchange Commission ("SEC"),  and should be
         read in  conjunction  with the audited  financial  statements and notes
         thereto  contained in  CytoGenix's  latest annual report filed with the
         SEC on Form  10KSB.  In the  opinion of  management,  all  adjustments,
         consisting  of  normal  recurring  adjustments,  necessary  for a  fair
         presentation  of financial  position and the results of operations  for
         the interim periods presented have been reflected  herein.  The results
         of operations for interim periods are not necessarily indicative of the
         results  to be  expected  for the full  year.  Notes  to the  financial
         statements which would substantially duplicate the disclosure contained
         in the audited  financial  statements for fiscal year 2002, as reported
         in the 10KSB, have been omitted.


         NOTE 2 - COMMON STOCK

         In  the  nine  months  ending  September  30,  2003,  CytoGenix  issued
         5,508,573  shares of common stock for  services  valued at $390,428 and
         sold 29,165,149 shares of common stock for $974,749.













<PAGE>

                                 CYTOGENIX, INC.
                          (A DEVELOPMENT STAGE COMPANY)


                                     PART I
ITEM 1   FINANCIAL STATEMENTS


ITEM 2            MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION.

         IN  ACCORDANCE  WITH  THE  "SAFE  HARBOR"  PROVISIONS  OF  THE  PRIVATE
SECURITIES  LITIGATION  REFORM  ACT OF 1995,  THE  COMPANY  NOTES  THAT  CERTAIN
STATEMENTS IN THIS FORM 10-QSB WHICH ARE FORWARD-LOOKING AND WHICH PROVIDE OTHER
THAN HISTORICAL INFORMATION, INVOLVE RISKS AND UNCERTAINTIES THAT MAY IMPACT THE
COMPANY'S RESULTS OF OPERATIONS. THESE FORWARD-LOOKING STATEMENTS INCLUDE, AMONG
OTHERS,   STATEMENTS  CONCERNING  THE  COMPANY'S  GENERAL  BUSINESS  STRATEGIES,
FINANCING  DECISIONS,  AND  EXPECTATIONS  FOR FUNDING CAPITAL  EXPENDITURES  AND
OPERATIONS  IN THE  FUTURE.  WHEN  USED  HEREIN,  THE WORDS  "BELIEVE,"  "PLAN,"
"CONTINUE,"  "HOPE,"  "ESTIMATE,"  "PROJECT,"  "INTEND,"  "EXPECT,"  AND SIMILAR
EXPRESSIONS ARE INTENDED TO IDENTIFY SUCH FORWARD-LOOKING  STATEMENTS.  ALTHOUGH
THE COMPANY  BELIEVES THAT THE  EXPECTATIONS  REFLECTED IN SUCH  FORWARD-LOOKING
STATEMENTS ARE BASED ON REASONABLE ASSUMPTIONS,  NO STATEMENTS CONTAINED IN THIS
FORM  10-QSB  SHOULD BE  RELIED  UPON AS  PREDICTIONS  OF  FUTURE  EVENTS.  SUCH
STATEMENTS ARE NECESSARILY DEPENDENT ON ASSUMPTIONS, DATA OR METHODS THAT MAY BE
INCORRECT OR IMPRECISE  AND MAY BE  INCAPABLE OF BEING  REALIZED.  THE RISKS AND
UNCERTAINTIES  INHERENT IN THESE  FORWARD-LOOKING  STATEMENTS COULD CAUSE ACTUAL
RESULTS  TO DIFFER  MATERIALLY  FROM  THOSE  EXPRESSED  IN OR  IMPLIED  BY THESE
STATEMENTS.

         READERS   ARE   CAUTIONED   NOT  TO  PLACE   UNDUE   RELIANCE   ON  THE
FORWARD-LOOKING  STATEMENTS  CONTAINED  HEREIN,  WHICH SPEAK ONLY AS OF THE DATE
HEREOF. THE INFORMATION CONTAINED IN THIS FORM 10-QSB IS BELIEVED BY THE COMPANY
TO BE ACCURATE AS OF THE DATE HEREOF. CHANGES MAY OCCUR AFTER THAT DATE, AND THE
COMPANY WILL NOT UPDATE THAT INFORMATION EXCEPT AS REQUIRED BY LAW IN THE NORMAL
COURSE OF ITS PUBLIC DISCLOSURE PRACTICES.

         IMPORTANT  RISK  FACTORS  THAT  COULD  CAUSE  ACTUAL  RESULTS TO DIFFER
MATERIALLY  FROM THE  EXPECTATIONS  REFLECTED IN ANY  FORWARD-LOOKING  STATEMENT
HEREIN  INCLUDE  AMONG OTHER  THINGS:  (1) THE ABILITY OF THE COMPANY TO QUICKLY
PENETRATE  THE MARKET  WITH ITS CURRENT  THERAPEUTIC  PRODUCTS  AGAINST  LARGER,
WELL-FINANCED COMPETITORS WITHIN THE MARKETPLACE; (2) THE ABILITY OF THE COMPANY
TO GENERATE  REVENUES IS  SUBSTANTIALLY  DEPENDENT UPON  CONTINUED  RESEARCH AND
DEVELOPMENT FOR, AND FDA APPROVAL OF, THERAPEUTIC  PRODUCTS;  (3) THE ABILITY OF
THE  COMPANY  TO  ATTRACT  AND  RETAIN  KEY  OFFICERS,  KNOWLEDGEABLE  SALES AND
MARKETING PERSONNEL AND HIGHLY TRAINED TECHNICAL  PERSONNEL;  (4) THE ABILITY OF
THE  COMPANY TO OBTAIN  ADDITIONAL  FINANCING  FROM  PUBLIC AND  PRIVATE  EQUITY
MARKETS TO FUND OPERATIONS AND FUTURE GROWTH; AND (5) THE ABILITY OF THE COMPANY
TO  GENERATE  REVENUES TO COVER  OPERATING  LOSSES AND  POSITION  THE COMPANY TO
ACHIEVE POSITIVE CASH FLOW.



<PAGE>


                                 CYTOGENIX, INC.
                          (A DEVELOPMENT STAGE COMPANY)



         The Company has budgeted $1,614,382 for operations in fiscal year 2003,
of which  $937,582 has been allocated for general and  administrative  costs and
$676,800 has been allocated for research and  development,  The Company has also
budgeted  $4,172,000 for operations in fiscal year 2004, of which $1,489,000 has
been  allocated for general and  administrative  costs and  $2,683,000  has been
allocated for research and development,

         The  Company  will rely on equity  financing  to  satisfy  its  working
capital  requirements,  and as of September 30, 2003 the Company had $178,492 in
cash on hand.

         There are currently over 800 U.S. patents for antisense  molecules with
therapeutic  potential,  each of which is a prospective licensee for CytoGenix's
technology.  The  Company  anticipates  entering  into  licenses  for a $100,000
initiation fee and either a minimum royalty fee of $50,000 per year or a royalty
fee equal to 15% of the licensee's net sales, whichever is greater.

         The Company's ability to continue  operations through December 31, 2003
and beyond  depends on its success in  obtaining  equity  financing in an amount
sufficient to support its  operations  through that date.  There is  substantial
doubt that the Company will be able to generate  sufficient  revenues or be able
to raise adequate  capital to remain a going concern through  December 31, 2003.
Based  on  historical  yearly  financial  requirements,   operating  capital  of
approximately  $1.7  million  and $4.2  million  will be needed  for each of the
calendar years 2003 and 2004.respectively.

         The Company  expects its sources of revenue for the next several  years
to consist primarily of payments under future product development joint ventures
and of  licensing  agreements  as well as  possible  royalties.  The  process of
developing the Company's products will require  significant  additional research
and development,  preclinical testing and clinical trials, as well as regulatory
approvals.   These   activities,   together  with  the  Company's   general  and
administrative expenses, are expected to result in operating losses for at least
two more years.  The Company will not receive product  revenue from  therapeutic
products unless it completes clinical trials and successfully  commercializes or
arranges for the  commercialization of one or more products,  the accomplishment
of which no assurance can be given.


CytoGenix has begun animal testing of its first DNA drug product candidate.  The
topical cream to be evaluated  will have  applications  against  genital  herpes
(HSV-2) and labial  herpes or cold sores  (HSV-1).  The HSV virus is known to be
highly evolved and its genome contains  instructions for several phases of viral
activity including infection,  replication,  production,  and latency. CytoGenix
proprietary  gene  regulation  technology  is being applied to inhibit key genes
that control one or more of these  functions,  which are critical for the Herpes
virus survival in the body.


During the past few months,  the Company has  continued  to refine its course of
developing  applications  for  its  core  technology.  Most  significant  is the
pre-clinical  program  for  an  anti-viral  HSV  topical  preparation.  We  have
teamed-up  with a group  of  leading  herpes  and STD  investigators  at a large
academic medical center to conduct a comprehensive cell and animal study program
designed to yield safety and efficacy data in preparation  for an IND submission
planned for April 2004 and subsequent human trials.


The Genomics  field has expanded the number of potential drug targets to several
thousand.  The CytoGenix  proprietary gene down-regulation  system is a powerful
tool in confirming gene target function.  In July 2002, we inaugurated a service
geared  towards  assisting  pharmaceutical  and biotech  companies  improve drug
discovery  efficiency.  In  addition  to our work on  in-house  targets,  we are
conducting  a pilot  studies  for  several  companies.  For a fixed fee, we will
knockdown a gene in a cell system. This will confirm the gene's relevance to the
disease of  interest.  Those  genes  found to be highly  disease-related  become
targets for new drug or molecular therapies.



<PAGE>

                                 CYTOGENIX, INC.
                          (A DEVELOPMENT STAGE COMPANY)

CytoGenix is confident about the Company's technology's ability to inhibit these
genes. This six to nine month program includes extensive toxicology and efficacy
studies in various model animals.

         The Company is subject to risks common to biopharmaceutical  companies,
including  risks inherent in its research and  development  efforts and clinical
trials,   reliance  on  collaborative   partners,   enforcement  of  patent  and
proprietary  rights,  the need for future  capital,  potential  competition  and
uncertainty in obtaining required regulatory approval. In order for a product to
be commercialized, it will be necessary for the Company and its collaborators to
conduct pre-clinical tests and clinical trials,  demonstrate efficacy and safety
of the Company's product candidates, obtain regulatory clearances and enter into
distribution and marketing  arrangements either directly or through sublicenses.
From the Company's  inception through the date of this document,  the major role
of  management  has been to obtain  sufficient  funding for  required  research,
monitoring research progress and developing and licensing intellectual property.

         The Company expects to incur losses for the  foreseeable  future due to
the ongoing  activities of the Company to develop new products  through research
and  development  and to develop joint  ventures and licensing  agreements  with
third parties. The Company expects its existing operations to continue to result
in negative  cash flow and working  capital  deficiencies  that will require the
Company to continue to obtain additional capital. There can be no assurance that
the necessary financing will be available to the Company or, if available,  that
the same will be on terms  satisfactory  or favorable to it. It is possible that
additional equity financing will be highly dilutive to existing shareholders.

         The Company is currently operating at a loss and expects to continue to
depend on cash generated from the sale of debt and equity securities to fund its
operating  deficit.  There can be no assurance  that the Company will be able to
generate sufficient revenues to meet its operating cash and growth needs or that
any equity or debt  funding  will be  available  or at terms  acceptable  to the
Company in the future to enable it to continue operating in its current form.



                                     PART II

ITEM 1.           LEGAL PROCEEDINGS.


The suit  styled  Charles  S. Boyd,  et al.,  Cause no.  2002-14038  in the 61th
District Court of Harris  County,  Texas was settled out of court as of November
20, 2003 with mutual releases by the parties of any and all claims. The terms of
the settlement are confidential.

ITEM 2.           CHANGES IN SECURITIES


         On August 7, 2003 the Company issued  7,303,493 shares of common stock.
Of these  shares,  7, 303,493  shares were sold for an  aggregate  cash price of
$219,105  (or $0.03 per share) in a private  placement to  accredited  investors
(Richard  Cecil-500,  000  shares,  Larry Masi - 200,000  shares,  Larry  Massi,
Maximum  Value  Promotions - 166,666  shares,  Rosemarie  Brokenshire  - 166,666
shares,  Donald Dow - 100,000  shares,  Bob Hydeman - 836,827  shares,  Marcus &
Diane Kuypers - 166,667 shares,  Frances Nelkin - 500,000  shares,  Vera & Cyril
Brandt - 600,000 shares, Peter Imbert - 333,333 shares, Richard Bean - 1,000,000
shares,  Steve Pearce - 166,667 shares,  Peter Imbert-  266,667  shares,  Thomas
Loucas -  200,000  shares,  Robert  Kirk - 100,000  shares,  Roland  Violette  -
2,000,000  shares ). pursuant to the  exemption  from  registration  provided by
Section 3(b) of the Securities Act of 1933 and Rule 504 thereunder)









<PAGE>

                                 CYTOGENIX, INC.
                          (A DEVELOPMENT STAGE COMPANY)


         On August 20, 2003,  the Company  issued 100,000 shares of common stock
(Corporate  Image  Bureau-  100,000  shares for  services  rendered  aggregating
$14,000  (or  $0.14 per  share)  pursuant  to the  exemption  from  registration
provided by Section 3(b) of the Securities Act of 1933 and Rule 504 thereunder.

         On September  22, 2003 the Company  issued  2,062,414  shares of common
stock.  Of these  shares,  346,080  were issued to executive  officers  (Malcolm
Skolnick-29,065 shares, Frank Vazquez- 42,349 shares, Yin Chen-65,184 shares and
Lawrence  Wunderlich- 105,362 shares) and employees (Xin-Xing Tan- 54,320 shares
and Harilyn  McMicken-  49,800 shares) of the Company as bonus for  compensation
for an  aggregate  price of $69,835 or an average of $0.076 per share  (based on
bonus of 20 % of annual gross salary  period) in reliance on the exemption  from
registration  provided  by  Section  4(2)  of the  Securities  Act of  1933  for
transactions  not involving a public offering.  Of these shares,  1,662,016 were
issued to (Hydeman Family Partners- 1,203,683 shares, Rick Barry- 30,000 shares,
John   Gattineri-   26,667  shares,   Kirk  Huntsman-   35,000  shares,   Donals
Lawler-50,000  shares,  Richard Cecil- 30,000 shares,  Andrew  Yosinoff-  20,000
shares,  and Douglas  Nelkin-266,666  shares) for services rendered  aggregating
49,820 (or $.03 per share).  The  remaining  shares were issued to (Scott Edward
Parazynski-  47,273  shares and Cy Stein-  7,045  shares)  for Board of Director
services rendered aggregating 5,000(or an average price of $.092 per share).


         On  September  30, 2003 the  Company  issued  442,857  shares of common
stock. Of these shares,  442,856 shares were sold for an aggregate cash price of
$62,000 (or $0.14 per share) in a private placement to accredited investors(John
Skubinski - 50,000 shares,  Eric Stocker - 142,857,  Paul Goldman- 100,000,  and
Don Edwards- 150,000,).  pursuant to the exemption from registration provided by
Section 3(b) of the Securities Act of 1933 and Rule 504 thereunder)













<PAGE>

                                 CYTOGENIX, INC.
                          (A DEVELOPMENT STAGE COMPANY)


ITEM 3.            DEFAULTS UPON SENIOR SECURITIES.

               NONE.

ITEM 4.           SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
               NONE


ITEM 5.           OTHER INFORMATION




ITEM 6            EXHIBITS AND REPORTS ON FORM 8-K

          (a)  Exhibits.

               Exhibit Number            Description


                  3.1*     Articles of  Incorporation  of  Cryogenic  Solutions,
                           Inc.

                  3.2*     Certificate  of Amendment  dated  November 1, 1995 of
                           Articles of  Incorporation  of  Cryogenic  Solutions,
                           Inc.

                  3.3*     Bylaws of Cryogenic Solutions, Inc.

                  99.1     Certification  pursuant to 18 U.S.C. Section 1350, as
                           adopted pursuant to Section 906 of the Sarbanes-Oxley
                           Act  of  2002  -  Chief   Executive   Officer   99.2.
                           Certification  pursuant to 18 U.S.C. Section 1350, as
                           adopted pursuant to Section 906 of the Sarbanes-Oxley
                           Act of 2002 - Chief Financial Officer


* Incorporated by reference to such Exhibit to the 10-SB of the Company filed on
January 31, 2001.

          (b) Financial Statement Schedules.

          All schedules are omitted  because they are not  applicable or because
the required  information is contained in the Financial  Statements or the Notes
thereto.

          (c) Reports on Form 8-K.

               None.



<PAGE>



                                   SIGNATURES

         In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

                                            CYTOGENIX, INC.

 Date: November 20, 2003                    By:  /s/  Malcolm Skolnick
                                                 ---------------------
                                                      MALCOLM SKOLNICK
                                                      PRESIDENT AND CHIEF
                                                      EXECUTIVE OFFICER